A Phase I/ II Study to Evaluate the Safety and Preliminary Efficacy of Nivolumab in Combination With Brentuximab Vedotin in Subjects With Relapsed Refractory Non Hodgkin Lymphomas With CD30 Expression (CheckMate 436: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 436)

Trial Profile

A Phase I/ II Study to Evaluate the Safety and Preliminary Efficacy of Nivolumab in Combination With Brentuximab Vedotin in Subjects With Relapsed Refractory Non Hodgkin Lymphomas With CD30 Expression (CheckMate 436: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 436)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 11 Aug 2017

At a glance

  • Drugs Brentuximab vedotin (Primary) ; Nivolumab (Primary)
  • Indications B cell lymphoma; Cutaneous T cell lymphoma; Diffuse large B cell lymphoma; Mycosis fungoides; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma; Sezary syndrome
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms CheckMate 436
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 08 Jun 2017 Planned number of patients changed from 120 to 146.
    • 08 Jun 2017 Planned End Date changed from 12 Nov 2018 to 13 Feb 2020.
    • 08 Jun 2017 Planned primary completion date changed from 14 Oct 2018 to 9 Jun 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top